Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reminyl Gets New Name – Razadyne – Ahead Of ER Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.

You may also be interested in...



Johnson & Johnson Creates Primary Care Unit From Ortho-McNeil And Janssen

PriCara will market primary care-focused products including Levaquin, Aciphex and Duragesic.

Johnson & Johnson Creates Primary Care Unit From Ortho-McNeil And Janssen

PriCara will market primary care-focused products including Levaquin, Aciphex and Duragesic.

Razadyne Paragraph IV Certification

The first ANDA with a Paragraph IV certification for Johnson & Johnson's Alzheimer's product Razadyne (galantamine, formerly Reminyl) was filed Feb. 28, according to FDA's May 3 updated list of filings

Related Content

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel